Literature DB >> 1503908

Antigenic modulation of metastatic breast and ovary carcinoma cells by intracavitary injection of IFN-alpha.

P Giacomini1, M Mottolese, R Fraioli, M Benevolo, I Venturo, P G Natali.   

Abstract

Antigenic modulation of major histocompatibility and tumour associated antigens was observed in neoplastic cells obtained from patients with pleural and abdominal effusions of breast and ovary carcinomas following a single intracavitary dose of 18 x 10(6) U recombinant IFN-alpha. This regimen resulted in antigenic modulation in seven out of 11 tested cases, suggesting a potential, although limited, responsiveness of at least a fraction of breast and ovary carcinoma cells to in situ biomodification with IFN-alpha.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1503908      PMCID： PMC1977801          DOI： 10.1038/bjc.1992.267

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


  12 in total

Review 1.  Interferon therapy in cancer: from imaginon to interferon.

Authors:  D Goldstein; J Laszlo
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

Review 2.  Monoclonal antibodies for analysis of the HLA system.

Authors:  F M Brodsky; P Parham; C J Barnstable; M J Crumpton; W F Bodmer
Journal:  Immunol Rev       Date:  1979       Impact factor: 12.988

3.  mAb KUL/05 identifies a denaturation-resistant determinant shared by class II MHC products DR, DQ and DP.

Authors:  P Giacomini; R Tecce; M R Nicotra; B B Cohen; M C Mazzilli; P G Natali
Journal:  J Immunogenet       Date:  1989-06

4.  Modulation of the antigenic phenotype of early-passage human melanoma cells derived from multiple autologous metastases by recombinant human leukocyte, fibroblast and immune interferon.

Authors:  P Giacomini; R Fraioli; P Nistico; R Tecce; M R Nicotra; F Di Filippo; P B Fisher; P G Natali
Journal:  Int J Cancer       Date:  1990-09-15       Impact factor: 7.396

5.  Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.

Authors:  J H Schiller; B Storer; P L Witt; B Nelson; R R Brown; M Horisberger; S Grossberg; E C Borden
Journal:  Cancer Res       Date:  1990-08-01       Impact factor: 12.701

6.  Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.

Authors:  P Allavena; F Peccatori; D Maggioni; A Erroi; M Sironi; N Colombo; A Lissoni; A Galazka; W Meiers; C Mangioni
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

7.  Immunological analysis of mucin molecules expressed by normal and malignant mammary epithelial cells.

Authors:  A B Griffiths; J Burchell; S Gendler; A Lewis; K Blight; R Tilly; J Taylor-Papadimitriou
Journal:  Int J Cancer       Date:  1987-09-15       Impact factor: 7.396

8.  Differential responsiveness of cloned mammary carcinoma cell populations to the human recombinant leukocyte interferon enhancement of tumor antigen expression.

Authors:  J W Greiner; M Tobi; P B Fisher; J A Langer; S Pestka
Journal:  Int J Cancer       Date:  1985-08-15       Impact factor: 7.396

9.  Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients.

Authors:  P Giacomini; R Fraioli; A M Calabrò; F Di Filippo; P G Natali
Journal:  Cancer Res       Date:  1991-01-15       Impact factor: 12.701

10.  Reactivity of a monoclonal antibody with human ovarian carcinoma.

Authors:  R C Bast; M Feeney; H Lazarus; L M Nadler; R B Colvin; R C Knapp
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.